Median Technologies Secures Up to €37.5 Million Financing from European Investment Bank

July 11, 2025 - 21:25

SOPHIA ANTIPOLIS, France, July 11, 2025—In a significant development for the healthcare technology sector, Median Technologies has announced the signing of a financial agreement with the European Investment Bank (EIB) that could provide up to €37.5 million in new financing. This agreement is expected to bolster Median's ongoing efforts in the field of artificial intelligence-powered medical devices, particularly its flagship product, eyonis®.

Eyonis® is a suite of Software as a Medical Device (SaMD) designed to enhance early cancer diagnosis through advanced AI algorithms. The funding from the EIB will enable Median to further develop its AI-based image analysis capabilities and expand its central imaging services for oncology drug developers. This strategic move aligns with the company's mission to improve cancer detection and treatment outcomes, leveraging cutting-edge technology to support healthcare professionals.

The partnership with the EIB not only underscores the growing importance of innovative financing solutions in the biotech industry but also highlights Median Technologies' commitment to advancing cancer care through technological innovation. As the company moves forward, it aims to make significant strides in the fight against cancer, ultimately benefiting patients and healthcare providers alike.